Two ets family members, namely erg and Fli-1 are fused with two EWS familiy members namely EWS and TLS/ FUS as a result of chromosome translocation in human solid tumors and leukemias. EWS-erg and EWS-Fli-1, which are involved in greater than 95% of Ewing family of tumors, were shown to function as transcriptional activators. TLS/FUS-erg, which is involved in human myeloid leukemias also functions as a transcriptional activator. Expression of these fusion proteins (EWS-erg and EWS-Fli-1) are shown to be essential for maintaining the oncogenic and tumorigenic properties of tumor cells. Cancer is thought to be caused not only by uncontrolled cell proliferation but also by deregulation of programmed cell death. Therefore, we have studied the role of normal (Fli-1 and erg) and aberrant fusion proteins (EWS-erg, EWS-Fli-1 and TLS/FUS-erg) in apoptosis. We have found that expression of normal (Fli-1 and erg) and aberrant fusion proteins inhibit the apoptosis of NIH3T3 cells induced by either serum deprivation or by treatment with calcium ionophore. We have also observed similar suppression of apoptosis in Ewing's sarcoma cells expressing EWS-Fli-1 and EWSerg proteins suggesting that these fusionproteins may be responsible for the decreased ability of these tumor cells to undergo apoptosis. Inhibition of the expression of these aberrant fusion proteins by antisense RNA technique resulted in increased susceptibility to apoptosis leading to the death of tumor cells. Therefore, our results suggest that one can use therapeutic agents which can down regulate the expression of fusion proteins in combination with chemotherapeutic agents as an eective treatment for these human solid tumors and leukemias.
Introduction
Ewing family of tumors (which includes Ewing's sarcoma of bone, primitive neuroectodermal tumors, Askin tumors, malignant ectomesenchymoma, olfactory neuroblastoma and extraskeletal Ewing's sarcoma) could account for the second most common soft tissue tumors in adolescents and young adults (Triche, 1993) .
Karyotype analysis of majority (greater than 95%) of Ewing family of tumors revealed a recurrent t(11;22) or t(21;22) chromosomal translocation suggesting that the aberrant fusion product of such chromosomal rearrangement may be responsible for these human malignancies (Mitelman, 1991; Rabbits, 1994; , Cleary, 1991; Delattre et al., 1992; Zucman et al., 1993a; Sorensen et al., 1994; Giovannini et al., 1994) . Molecular characterization of these Ewing's family of tumors revealed fusion of EWS gene, on chromosome 22, with either Fli-1 or erg genes (ets family members), located on chromosomes 11 and 21, respectively (Delattre et al., 1992; Zucman et al., 1993a; Sorensen et al., 1994; Giovannini et al., 1994; Dunn et al., 1994) . We and others have earlier identi®ed, cloned and characterized two ets genes namely erg Prasad et al., 1994a; Duterque-Coquillaud et al., 1993) and Fli-1 (Prasad et al., 1992; Ben-David et al., 1991; Watson et al., 1992; Klemsz et al., 1993) . Functional analysis of Fli-1 and erg proteins revealed that these proteins code for sequence speci®c transcriptional activators with two transcriptional activation domains, one is present at the amino terminal region and the other at the carboxyl terminal region (Reddy and Rao, 1991; Siddique et al., 1993; Rao et al., 1993) . We have shown that EWS gene (other fusion partner) codes for an RNA binding protein which speci®cally binds to poly G and poly U (Ohno et al., 1994) . Interestingly, this EWS gene is also fused with a variety of transcriptional factors which includes ATF-1, WT1, ER81/ETC1, CHOP and PEA3 in dierent solid tumors (Zucman et al., 1993b, Ladanyi and Gerald, 1994; Gerald et al., 1995; Jeon et al., 1995; Panagopoulos et al., 1996; Kaneko et al., 1996; Clark et al., 1996) . Therefore studying the functional aspects of EWS-fusion proteins (EWS-erg and EWS Fli-1) may provide a clue for the activation of EWS-fusion products in a wide spectrum of cancers.
We and others have shown that EWS-Fli-1 and EWS-erg proteins encode transcriptional activators ( Figure 1 ) May et al., 1993; Bailly et al., 1994) . Amino terminal region of EWS protein is shown to function as a regulatory domain or as a transactivator domain depending on the target sequences May et al., 1993; Bailly et al., 1994; Fujimura et al., 1996; Prasad and Reddy, unpublished results) . Aberrant EWS-erg proteins show altered DNA binding and transcriptional activation properties compared to normal erg proteins (Ohno et al., 1994) . Our recent results show that targeting the EWS-fusion products (EWS-Fli-1 and EWS-erg) of Ewing's sarcoma cells results in a loss of tumorigenicity of these tumor cells suggesting that a certain threshold level of expression of EWS-fusion products are needed for the clonogenicity and tumorigenicity of Ewing's sarcoma cells (Ouchida et al., 1995; Kovar et al., 1996) . TLS/FUS, a gene related to EWS, is also fused with erg gene in human myeloid leukemia with t(16;21)(p11;q22) chromosome translocation ( Figure  1 ) (Shimizu 1993; Ichikawa et al., 1994; Panagopoulos et al., 1994; Helm et al., 1994; Crozat et al., 1993; Rabbitts et al., 1993) . Functional analysis of TLS/FUS protein revealed that this protein also functions as a RNA binding protein. We have shown that aberrant TLS/FUS-erg functions as a transcriptional activator (Prasad et al., 1994b) and the TLS/FUS fusion domain contributes transcriptional activation domain to the TLS/FUS-erg chimeric protein (Prasad et al., 1994b; Sanchez-Garcia and Rabbitts, 1994; Zinszner et al., 1994) . TLS/FUS-erg shows altered DNA binding properties and consequently shows altered transcriptional activation properties (Prasad et al., 1994b) . It is possible that altered DNA binding and transcriptional activation functions may be responsible for the oncogenic potential of the EWS and TLS/FUSchimeric proteins. Sequestering of critical factors (CBP/p300) through protein-protein interactions of these chimeric proteins may also be responsible for tumor formation (Fujimura et al., 1996) . Interestingly, TLS/FUS and erg genes (involved in solid tumors) are fused together in the human myeloid leukemia with t(16;21)(p11;q22) chromosome translocation suggesting that there may be a common pathway for transaformation of human solid tumors and leukemias.
Cancer is thought to be a disease caused as a result of uncontrolled cell proliferation. Recent studies on oncogenes such as bcl-2 revealed that it is not necessary that all oncoproteins have to play a role in cell proliferation but they can regulate apoptosis/programmed cell death of certain types of cells leading to malignant transformation. There is a growing list of oncogene/tumor suppressors gene products that regulate the apoptosis which includes c-myc, p53, Rb, ras, rho, brc-abl and BRCA1 (Canman and Kastan, 1995; Bedi et al., 1994; McGahon et al., 1994; Shao et al., 1996; Thompson, 1995; Homan and Liberman, 1994) . Therefore, it is important to study the role of normal and aberrant Fli-1 and erg proteins in apoptosis to assess their role in cell growth, dierentiation and neoplasia.
In order to study the role of normal and aberrant Fli-1 and erg proteins in apoptosis, we have obtained permanent NIH3T3 cell lines expressing normal Fli-1 and erg and also their aberrant fusion proteins (EWSFli-1, EWS-erg and TLS/FUS-erg). Our results demonstrate that these normal and aberrant fusion proteins inhibit apoptosis induced by either serum deprivation or by calcium ionophore treatment. Ewing sarcoma cells expressing these aberrant fusion proteins show resistance to apoptosis induced by chemotherapeutic agents. However targeting the fusion proteins of Ewing sarcoma cells (by antisense RNA technique) resulted in increased susceptibility to apoptosis induced by chemotherapeutic agents. These results demonstrate that one can use therapeutic agents that target/down regulate the expression of fusion proteins in combination with chemotherapeutic drugs that induce apoptosis as an eective treatment for human solid tumors and leukemias. Our results suggest that Fli-1 and erg proteins may play a role in cell growth and differentiation through apoptotic pathway. 
Results and Discussion
To study the role of fusion proteins (EWS-Fli-1, EWSerg and TLS/FUS-erg) and their normal counterpart (Fli-1 and erg) in apoptosis, we have obtained permanent NIH3T3 cell lines expressing normal and aberrant Fli-1 and erg proteins. We have transfected NIH3T3 cells with pcDNA expression vector or pcDNA expression vectors containing Fli-1 (Prasad et al., 1992) , erg Rao et al., 1987) , EWS-Fli-1 (Ohno et al., 1994) , EWS-erg (Ohno et al., 1994) or TLS/FUS-erg (Prasad et al., 1994b) cDNAs and obtained stable G418 resistant cell lines expressing normal erg and Fli-1 and their aberrant fusion proteins. These cell lines were analysed for the expression of appropriate transfected gene by immunouorescence and/or immunoprecipitation. These cell lines showed signi®cant level of expression of erg, EWS-erg, TLS/FUS-erg, Fli-1 and EWS-Fli-1 proteins ( Figure 2 ). Immuno¯uorescence results suggest that both normal and aberrant erg and Fli-1 proteins are localized mostly in the nucleus of the transfected cells (data not shown).
Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins
Earlier calcium ionophore, A23187, was used effectively to induce apoptosis in thymocytes (McConkey et al., 1989) . This led us to study apoptosis in Fli-1 and EWS-Fli-1 transfected cells during A23187 treatment. NIH3T3, Fli-1 and EWS-Fli-1 (two independent clones) transfected cells were treated with calcium ionophore A23187 for 24 h and the cell cycle distribution was determined by¯ow cytometry with propidium iodide staining method (Shao et al., 1996) . Histogram of the DNA content and percentage of cells in G 1 , S and G 2 plus M of the cell cycle were evaluated by computer analysis using EPICS pro®le analyzer. NIH3T3 cells treated with calcium ionophore showed signi®cant levels of apoptosis (A 0 value 39%) as measured by the appearance of hypodiploid DNA peak on¯ow cytometry ( Figure 3a ). However Fli-1 and EWS-Fli-1 transfected cells showed G 1 arrest and decreased rate of apoptosis (A 0 value 2 ± 3%) during calcium ionophore treatment. Since FACS analysis suers from disadvantage of no distribution between viable and dead cells, the viability of both NIH3T3 cells and Fli-1 and EWS-Fli-1 transfected cells cultured in the presence of calcium ionophore was tested by crystal violet staining. Cell viability staining showed that the majority of the NIH3T3 cells treated with calcium ionophore A23187 were dead whereas most of the Fli-1 and EWS-Fli-1 transfected cells survived (data not shown). These results suggest that both Fli-1 and EWS-Fli-1 inhibit apoptosis induced by calcium ionophore. We have also con®rmed the inhibition of apoptosis in Fli-1 and EWS-Fli-1 transfected cells by DNA fragmentation assay. Control NIH3T3 cells treated with calcium ionophore showed DNA fragmentation typical of apoptosis, whereas Fli-1 and EWS-Fli-1 transfected cells show decreased DNA fragmentation (Figure 3b ). These results support the above observation that Fli-1 and EWS-Fli-1 inhibit apoptosis induced by calcium ionophore.
These results led us to test whether other fusion proteins such as EWS-erg and TLS/FUS-erg (involved in human solid tumors and also in human leukemias) also inhibit apoptosis of cells induced by calcium ionophore treatment. We followed similar approaches described above to study the role of erg, EWS-erg and TLS/FUS-erg in apoptosis. Flow cytometry analysis of erg, EWS-erg and TLS/FUS-erg transfected cells (Figure 4a) showed G 1 arrest and decreased rate of apoptosis (A 0 value 2 ± 3%) during calcium ionophore treatment. Under similar conditions the control NIH3T3 cells showed high levels of apoptosis (A 0 value 39%).
In viability assays with crystal violet staining, most of control NIH3T3 cells are not viable after 24 h Figure 4b shows that DNA of control NIH3T3 cells showed readily DNA fragmentation whereas the erg, EWS-erg and TLS/FUS-erg transfected cells treated with calcium ionophore showed decreased DNA fragmentation. Serum starvation was shown to be one of the potent inducers of apoptosis. Therefore we wanted to know what role these normal and aberrant Fli-1 and erg proteins play in the apoptosis induced by serum withdrawal. Analysis of DNA fragmentation of transfectants induced by serum starvation/deprivation con®rmed the activation of apoptosis/programmed cell death with the production of DNA ladder (data not shown). This DNA ladder pattern was evident in the 4 cells were seeded into 24 well culture dishes and cultured in complete DMEM medium for 3 days. The medium was discarded and the cells were cultured in serum free medium for indicated time. Both adherent and nonadherent cells were pooled and stained with trypan blue and counted. The error bar represents mean and standard deviation of two to three separate experiments. (b) Eect of erg, EWS-erg or TLS-erg on the cell viability of NIH3T3 cells subjected to serum starvation by trypan blue staining NIH3T3 transfectants (empty vector)(data not shown). However NIH3T3 transfectants expressing Fli-1 and EWS-Fli-1 showed decreased DNA fragmentation (data not shown). These results suggest that Fli-1 and EWS-Fli-1 may be suppressing apoptosis. Cell viability was assessed based on the ability of cells to exclude trypan blue dye. NIH3T3 control transfectants died with accelerated kinetics compared to NIH3T3 transfectants expressing Fli-1 and EWS-Fli-1 (Figure  5a ). At 48 h after serum deprivation, 35 ± 45% of control NIH3T3 cells were alive compared to 60% of NIH3T3 transfectants expressing Fli-1 and EWS-Fli-1 (Figure 5a ). These results also con®rm the inhibition of apoptosis (induced by serum starvation) by Fli-1 and EWS-Fli-1. Similarly, we have also studied the relationship between expression of erg, EWS-erg and TLS/FUS-erg and inhibition of apoptosis induced by serum withdrawal. Control NIH3T3 cells readily showed DNA fragmentation after 60 h withdrawal of serum indicating activation of apoptosis (data not shown). However erg, EWS-erg and TLS/FUS-erg transfected cells showed decreased DNA fragmentation after 60 h withdrawal of serum (data not shown). These ®ndings indicate that erg, EWS-erg and TLS/ FUS-erg inhibit the rate of cell death in serumdeprived NIH3T3 cells. These results were also con®rmed by the assessment of viability of cells using trypan blue exclusion assay ( Figure 5b ). As shown in Figure 5b , erg, EWS-erg and TLS/FUS-erg transfected cells died with decreased kinetics compared to control NIH3T3 cells. This phenomenon is exempli®ed at 48 h after serum withdrawal, where only 40% of control NIH3T3 cells remained viable compared to 60 ± 70% of erg or EWS-erg or TLS/FUS-erg transfected cells (Figure 5b ). These ®ndings indicate that erg, EWSerg and TLS/FUS-erg suppress apoptosis induced by serum withdrawal. Therefore it appears that both EWS-and TLS/FUS-fusion proteins inhibit apoptosis and prolong the life of the tumor cells suggesting that other fusion proteins (EWS-ATF-1, EWS-WT1, EWS-ER81/ETV1, EWS-PEA3 and EWS-CHOP) involved in a variety of solid tumors may also exhibit similar function. Our recent results show that EWS-ATF-1 also inhibit apoptosis supporting the above conclusions (Reddy et al., unpublished results) . It remains to be seen how these fusion proteins inhibit apoptosis.
Since Fli-1 and erg proteins are expressed at high levels in hematopoietic cells and also inhibit apoptosis, it is possible that both Fli-1 and erg proteins play a key role in the dierentiation of hematopoietic cells through regulation of apoptosis. Such regulation of dierentiation through apoptotic pathways of T cells was previously attributed to another ets protein, c-ets-1 (Bories et al., 1995) . Friend murine leukemia virus (FMuLV) may have exploited this function (inhibition of apoptosis) of Fli-1 in erythroid cells resulting in erythroleukemias (Ben-David et al., 1991) . It remains to be seen whether transcriptional activation function of normal and aberrant erg or Fli-1 has any role in the inhibition of apoptosis.
Both fusion partner domains are required for ecient inhibition of apoptosis
In order to understand the role of fusion domains in the inhibition of apoptosis, we tested each of the fusion partner domains for their ability to inhibit apoptosis. For this experiment, we have cloned erg-, EWS-and TLS/FUS-fusion domains (Figure 1) into the expression vector pcDNA3, transfected them into NIH3T3 cells and obtained stable cell lines expressing these fusion domains (data not shown). We tested each of Figure 6 ) and DNA fragmentation assay (data not shown) revealed that both EWS-, TLS/FUS-and erg-fusion partner domains showed decreased inhibition of apoptosis unlike their full length fusion proteins. These results suggest that both fusion partner domains are required for ecient inhibition of apoptosis.
Down regulation of EWS-fusion proteins results in increased susceptibility to apoptosis of Ewing's sarcoma cells
The above results suggested that aberrant fusion proteins (EWS-erg and EWS-Fli-1) may function as anti-apoptotic factors in Ewing's sarcoma cells. Therefore we predicted that Ewing's sarcoma cells expressing these fusion proteins may show resistant to apoptosis. We also hypothesized that if one down regulates the expression of aberrant fusion proteins in Ewing's sarcoma cells, these tumor cells may become susceptible to apoptosis. To test these predictions, we have utilized the Ewing sarcoma cell lines (TC135 or 5838) that were transfected with either empty expression vector or the same vector carrying cDNA antisense to EWS-fusion transcripts (Ouchida et al., 1995) . These antisense plasmid transfected cell lines showed signi®cant (80 ± 90%) inhibition of expression of EWS-fusion proteins as judged by immunoprecipitation (Ouchida et al., 1995) . Topoisomerase II poison Etoposide (VP-16) and actinomycin D were used successfully to induce apoptosis in several cells (McGahon et al., 1994) . This led us to test the eect of these agents on the apoptosis of Ewing sarcoma cells transfected with either empty vector or antisense EWSfusion plasmid (Figure 7a ± d) . TC135 represent Ewing sarcoma cells carrying t(11;22) chromosome translocation which express EWS-Fli-1 fusion protein ( Figure  1 ). As shown in Figure 7a , TC135 cells transfected with empty expression vector showed resistance to the induction of apoptosis upon exposure to etoposide, whereas the TC135 cells transfected with expression vector containing antisense EWS-Fli-1 underwent apoptosis with accelerated rate. Only 40% of antisense EWS-Fli-1 transfected cells remained viable after 48 h treatment with etoposide, compared to nearly 95% of control TC135 cells transfected with empty vector (Figure 7a ). These results suggested that down regulation of expression of EWS-Fli-1 fusion protein results in increased susceptibility to apoptosis. Similar observation was also seen in the case of Ewing's sarcoma cells (5838) expressing EWS-erg fusion protein (Figure 7b ). 5838 cells transfected with empty vector showed resistance to apoptosis induced by treatment with etoposide whereas the 5838 cells transfected with antisense EWS-erg plasmid died with accelerated kinetics. Close to 25% of 5838 cells transfected with antisense EWS-erg died upon treatment with etoposide unlike the control 5838 cells (transfected with empty vector) which showed complete resistance to apoptosis (Figure 7b ). These results strongly suggest that 5838 cells become more susceptible to apoptosis after inhibition of expression of EWS-erg proteins. These results were also con®rmed by viability assay with crystal violet staining (Figure 7c and d) . Antisense transfected Ewing's sarcoma cells showed sensitivity to etoposide after 24 or 48 h treatment unlike the wild type Ewing's sarcoma cells transfected with empty vector (Figure 7c and d) . These results suggest that a certain threshold level of expression of EWS-fusion products are needed for inhibition of apoptosis.
We have also observed similar phenomenon in the case of another apoptotic inducer actinomycin D. Control empty vector transfected TC135 and 5838 cells showed resistance to apoptosis (Figure 8a) . However, antisense plasmid transfected TC135 and 5838 cells underwent apoptosis readily compared to control transfected cells. As shown in Figure 8a compared to 1 ± 2% of control transfected cells ( Figure  8b ). These results suggest that there is a correlation between down regulation of expression of EWS-fusion proteins and the increased susceptibility of the Ewing's sarcoma cells to cell death. Therefore one can use therapeutic agents that can inhibit or target the expression of fusion proteins in combination with chemotherapeutic agents (that induce apoptosis) for eective treatment of solid tumors and leukemias. Such methods were used successfully by others in the case of chronic myelogenous leukemic cells (McGahon et al., 1994) .
Materials and methods

Immunoprecipitation
Con¯uent stable NIH3T3 cells transfected with the appropriate gene of interest were labeled with [ 35 S]-translabel for 3 ± 4 h. The cells were lysed in RIPA buer and subjected to immunoprecipitation using anti erg or preimmune serum Ouchida et al., 1995) .
Immuno¯uorescence NIH3T3 cells (transformed by Fli-1, EWS-Fli-1, erg, EWSerg or TLS/FUS-erg) were cultured on microscope culture slides, washed in PBS and then ®xed in 3.5% formaldehyde in PBS for 15 min. Following ®xation, slides were immersed in a 3% BSA and 0.5% Triton X-100 in PBS to permeabilize cell membranes and block nonspeci®c antibody binding. The slides were then incubated for 45 min with primary antibody diluted in blocking solution (0.2% Tween-20 and 0.2% sodium azide in PBS). After washing, slides were incubated for 45 min with¯uorescein-conjugated secondary antibodies (goat anti-rabbit serum) diluted 1 : 500 in blocking solution. Finally, slides were washed with PBS, mounted using a solution of Vectashield and examined by confocal microscope and photographed.
Flow cytometry analysis
NIH3T3 cells or appropriate gene (Fli-1 or erg or EWSFli-1 or EWS-erg or TLS-erg) transfected cells were cultured in complete DMEM medium containing 10% FBS for 3 days and treated with 20 mM calcium ionophore A23187 for 24 h. Both adherent and nonadherent cells were pooled and ®xed in 70% cold ethanol in PBS for at least 30 min on ice. Cells were pooled, washed in PBS and stained with propidium iodide (20 mg/ml) and incubated with 20 mg/ml of RNAse A for at least 30 min. Samples were analysed using a EPIC pro®le analyzer. Histograms showing the total DNA content as Fl 2 vs cell number are shown.
Cell viability assays
In some cases cell viability was assessed either by their ability to exclude trypan blue. 1610 4 cells were seeded in 24 well culture plates and cultured for 3 days in a complete DMEM medium. The medium was discarded and the cells were cultured in serum free medium for indicated time. Both adherent and nonadherent cells were pooled and stained with trypan blue and counted the stained or unstained cells.
In certain cases, cell viability was assayed with crystal violet staining method. The cells were cultured in a complete DMEM medium (10% FBS) as described above and treated with 20 mM calcium ionophore A23187 for 24 h. Then the cells were washed two times with PBS and ®xed in cold 70% methanol for at least 30 min at 7208C. Cells were stained with crystal violet. The cells were washed with PBS and visualized under an Olympus microscope at 2006 magnification.
DNA fragmentation assay
1610
6 cells were seeded into 150 mm culture dish and grown in complete DMEM supplemented with 10% FBS for 1 day before treatment with calcium ionophore or withdrawal of serum. After the indicated treatment period, both adherent and nonadherent cells were pooled, washed with cold PBS and lysed the cells by incubating in 1 ml of lysate buer (10 mM Tris-HCl pH 8.0, 10 mM EDTA and 1% Triton X-100) for 10 min on ice. The lysate was centrifuged at 14 000 r.p.m. for 5 min. The supernatant was extracted with phenol: chloroform and the DNA was alcohol precipitated as described (Shao et al., 1996) . These samples were dissolved in 20 ml of water and ml of RNAse A (1 mg/ml) was added and incubated at 378C for 30 min. These DNA samples were analysed by electrophorresis in a 1.5% agarose gel and visualized by ethidium bromide staining.
MTT metabolic assay
Cell survival after the treatment of etoposide or actinomycin D was assessed by MTT assay. Viable cells will cleave MTT to produce formazan using mitochondrial enzyme succinate tetrazolium reductate. The quantity of formazan dye produced correlates directly to the number of viable cells. The metabolic assay was carried out as described earlier (Mosmann, 1983) . Brie¯y, 1610 6 cells were treated with etoposide or actinomycin D for indicated periods. The cells were washed with cold PBS and seeded (5610 4 cells/well) into 24 well culture dish and cultured for 4 h in DMEM supplemented with 10% FBS before MTT assay was carried out. Cells were incubated with MTT solution (500 mg/ml) for 2 h and the formazan was solubilized by thorough mixing with equal volume of acidic isopropanol (0.04 N HCl in isopropanol) and quantitated by measurement of absorbance at 570 Zm. The dierence of relative numbers of absorbance before and after the treatment with etoposide or actinomycin D represent the number of surviving cells.
